PaySign Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
FY Revenue (est.)
$108.6Mnext fiscal year
FY EPS (est.)
$0.33next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Active Patient Affordability Programs Quarterly141.0Target: 147-150 active programs by end of Q2 2026
Active Plasma Centers Quarterly554.0Target: 555-560 active centers by end of Q2 2026
Total Revenue Growth Rate Quarterly5,080.0%Target: 30.0% to 35.0% for FY 2026
Adjusted EBITDA Margin Quarterly3,780.0%Target: 28.0% to 30.0% for FY 2026
Watch Items
- Plasma Center Churn and Support Cost PressuresTrigger: Active programs falling below 145 in Q2 2026Action: Re-evaluate sales pipeline and client onboarding bottlenecks.
- Plasma Center Expansion and Donor Volume NormalizationTrigger: Plasma revenue growth dropping below 15% YoYAction: Assess competitive pressure from alternative payment providers and evaluate SaaS platform adoption.
Research as of 20 Jun 2026